RAPT Therapeutics 과거 수익 실적
과거 기준 확인 0/6
RAPT Therapeutics's earnings have been declining at an average annual rate of -23.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 16.2% per year.
주요 정보
-23.2%
수익 성장률
68.2%
EPS 성장률
| Biotechs 산업 성장 | 17.0% |
| 매출 성장률 | -16.2% |
| 자기자본 수익률 | -110.3% |
| 순이익 | n/a |
| 최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16수익 및 비용 분석
RAPT Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -120 | 28 | 101 |
| 31 Mar 24 | 0 | -118 | 28 | 100 |
| 31 Dec 23 | 0 | -117 | 26 | 101 |
| 30 Sep 23 | 0 | -109 | 25 | 94 |
| 30 Jun 23 | 0 | -99 | 23 | 83 |
| 31 Mar 23 | 1 | -93 | 21 | 76 |
| 31 Dec 22 | 2 | -84 | 20 | 67 |
| 30 Sep 22 | 2 | -79 | 20 | 62 |
| 30 Jun 22 | 3 | -76 | 18 | 61 |
| 31 Mar 22 | 3 | -73 | 17 | 60 |
| 31 Dec 21 | 4 | -69 | 16 | 57 |
| 30 Sep 21 | 4 | -64 | 15 | 54 |
| 30 Jun 21 | 5 | -60 | 14 | 51 |
| 31 Mar 21 | 5 | -56 | 13 | 49 |
| 31 Dec 20 | 5 | -53 | 13 | 45 |
| 30 Sep 20 | 4 | -53 | 12 | 45 |
| 30 Jun 20 | 2 | -49 | 10 | 40 |
| 31 Mar 20 | 1 | -47 | 10 | 38 |
| 31 Dec 19 | 0 | -43 | 9 | 35 |
| 30 Sep 19 | 0 | -39 | 7 | 33 |
| 30 Jun 19 | 0 | -40 | 7 | 34 |
| 31 Mar 19 | 0 | -37 | 6 | 32 |
| 31 Dec 18 | 0 | -36 | 5 | 32 |
양질의 수익: RAPT is currently unprofitable.
이익 마진 증가: RAPT is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: RAPT is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.
성장 가속화: Unable to compare RAPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: RAPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
자기자본 수익률
높은 ROE: RAPT has a negative Return on Equity (-110.26%), as it is currently unprofitable.